Result for
Tag: vaccines
June 3, 2021
Structural Analysis of the Novel Variants of SARS-CoV-2 and Forecasting in North America
A forecasting model incorporating North American prevalence of SARS-CoV-2 variants of concern from the genome database GISAID suggests that the B.1.1.7 variant could become dominant (>60% of sequenced strains) by summer 2021 but would sharply decrease in frequency when 75% of the population is immune through vaccination or natural infection due to its high binding…
June 2, 2021
Stopping the Misinformation BNT16b2 COVID-19 Vaccine Has No Negative Effect on Women’s Fertility
[Pre-print, not peer-reviewed] A study of 47 women undergoing in vitro fertilization (IVF) in Israel found no significant differences in IVF cycle outcomes in all participants prior to and after receiving the Pfizer-BioNTech vaccine, suggesting that vaccination has no negative effect on fertility using assisted reproductive technology. No significant differences were observed in the number…
Previous COVID-19 Infection, but Not Long-COVID, Is Associated with Increased Adverse Events Following BNT162b2/Pfizer Vaccination
History of COVID-19 infection was associated with greater odds of reporting at least one moderate-to-severe adverse event symptom following the first dose of the Moderna vaccine (56% vs 47%, OR=1.5), according to an analysis of data from a self-reported electronic survey of healthcare workers in England (n=974; 27% with PCR- or serology-confirmed infection). After adjusting…
Safety and Immunogenicity of a Recombinant DNA COVID-19 Vaccine Containing the Coding Regions of the Spike and Nucleocapsid Proteins Preliminary Results from an Open-Label Phase 1 Trial in Healthy Adults Aged 19-55 Years
[Pre-print, not peer-reviewed] An open-label phase 1 trial in Korea for the recombinant COVID-19 DNA vaccine candidates GX-19 and GX-19N (Genexine, Inc.) (n=61) found that geometric mean titers (GMTs) of anti-SARS-CoV-2 antibodies elicited by vaccination were lower than convalescent sera (although higher than pre-vaccination sera). GX-19N-elicited T-cell responses were stronger than GX-19 and were similar…
June 1, 2021
Neutralization Heterogeneity of United Kingdom and South-African SARS-CoV-2 Variants in BNT162b2-Vaccinated or Convalescent COVID-19 Healthcare Workers
97% (28 of 29) of healthcare workers with no prior infection had neutralizing activity against the SARS-CoV-2 B.1.351 variant of concern in their sera 1 week after receiving the second dose of the Pfizer-BioNTech vaccine, compared to only 60% (9 of 15) of healthcare workers who had COVID-19 6 months earlier. Geometric mean titers (GMTs)…
Correlation of Vaccine-Elicited Antibody Levels and Neutralizing Activities against SARS-CoV-2 and Its Variants
[Pre-print, not peer-reviewed] Analysis of sera from individuals fully vaccinated with the Pfizer-BioNTech (n=30) and Moderna (n=19) vaccines ≥22 days after the second dose showed that neutralizing activity against pseudoviruses bearing mutated spike proteins from variants of concern was detectable in all participants but was reduced by 7-10 fold against the B.1.351 variant. Anti-SARS-CoV-2 IgG…
Rate and Risk Factors for Breakthrough SARS-CoV-2 Infection After Vaccination
Breakthrough infection rates were not statistically significantly different by sex or the type of mRNA vaccine administered, according to an analysis of data from a cohort of US veterans (n=14,875). Risk of breakthrough infection increased with age (HR=1.11) and presence of anemia (HR=1.37) and was lower among Black vs white veterans (HR=0.65). The 410 breakthrough…
May 28, 2021
Effectiveness of BNT162b2 and MRNA-1273 COVID-19 Vaccines against Symptomatic SARS-CoV-2 Infection and Severe COVID-19 Outcomes in Ontario Canada
[Pre-print, not peer-reviewed] COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) were 60% effective against symptomatic SARS-CoV-2 infection 14-20 days after the first dose and 91% effective ≥7 days after the second dose in a test-negative study among symptomatic adults in Ontario, Canada between December 2020 and April 2021 (n=324,033). Vaccine effectiveness against severe outcomes was 62%…
Patterns in COVID-19 Vaccination Coverage, by Social Vulnerability and Urbanicity — United States, December 14, 2020–May 1, 2021
As of May 1, 2021, vaccination coverage was lower among US adults living in counties with higher social vulnerability (social and structural factors associated with adverse health outcomes) and with higher percentages of households with children, single parents, and persons with disabilities. By May 1, vaccination coverage was lower among adults living in counties with…
May 27, 2021
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
A randomized trial of the Pfizer-BioNTech vaccine (BNT162b2) among adolescents ages 12-15 reported vaccine efficacy of 100% (75.3-100%) against COVID-19 for the 2-dose vaccine series. There were 16 cases of COVID-19 among 1,129 placebo recipients and no COVID-19 cases among 1,131 vaccine recipients that occurred 7 or more days after the second dose among participants…
Previous page Next page